Catalent today announced that Mike Riley, Region President, Biologics, North America, will present at the upcoming Disease Prevention & Control Summit, taking place virtually on July 28 – 29, 2020.

Catalent today announced that it plans to invest $30 million (€27 million) at its facility in Limoges, France, to create a European center of excellence for clinical biologics formulation development and drug product fill-finish services.

Catalent and Humanigen today announced the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab.

Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca and prepare for large-scale commercial supply of the COVID-19 vaccine candidate, AZD1222.

Catalent today announced that a number of its experts will present at the upcoming Controlled Release Society (CRS) Annual Meeting, which will take place virtually on June 29 – July 2, 2020.

Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca and prepare for large-scale commercial supply of the COVID-19 vaccine candidate, AZD1222.

Catalent today announced that it has signed an agreement with Spicona, Inc. to develop a virus-like protein (VLP)-based vaccine against COVID-19 at its Madison, Wisconsin facility.

Catalent today announced that John Chiminski, Chair and Chief Executive Officer, will join other R&D leaders to present during BIO Digital, which will take place on June 8 – 12, 2020.

Catalent today announced that Jean-François Chaubard, Senior Director, Open Innovation at Catalent Cell & Gene Therapy, will be presenting at the ISCT 2020 Paris Virtual conference.